Eczema affects approximately 30 million people in the U.S. of which Atopic Dermatitis (AD) is the most common form. As you are aware, the condition affects both children and adults and is one of the most common skin complaints in the nation. Join LiVDerm this October as we highlight the varying impacts of this condition on patients and their families and examine some of the recent developments and treatment options for AD.
CME Activities
In view of Ezcema Awareness Month, we invite you to take advantage of our complimentary CME activities related to Atopic Dermatitis. Use these valuable resources to boost your knowledge and gain valuable insight into some of the challenges to treatment. One factor, in particular, taking the lead in current discussions is the disparities in tackling AD in patients with skin of color. Visit LiVDerm’s CME Education Lab for more information on the activities available, including:
LiVDerm has recently launched our “Articles” page, a brand new resource on our site designed to bring you the latest industry news, insights, and hot topics as they emerge. Simply head to this link for the latest feature.
As always, we want to know what you want to see more of to help you enhance your knowledge in the field! We invite you to please get in touch with us and share your thoughts and suggestions. You can reply to any of our emails or send an email to info@livderm.org. We look forward to hearing from you!
South Beach Symposium 2023
As you may already know, registration for the South Beach Symposium (SBS) 2023 and the Masters of Pediatric Dermatology Symposium (MOPD) 2023 is now open! Both of these incredible live events will take place at the Loews Miami Beach Hotel in February 2023. Our expert faculty and planning team are preparing the jam-packed agendas and these will be available on the website soon.
In the meantime, you can head to the registration page to book your seat at SBS and MOPD 2023.
FDA Approval of Sotyktu (deucravacitinib)
The U.S. Food and Drug Administration recently approved Bristol Myers Squibb’s Sotyktu (deucravacitinib). It is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of adults with moderate-to-severe plaque psoriasis. This recent approval is welcome news for both patients and health care professionals. Read more about it here.
Atopic Dermatitis Patient Case
Staying abreast of the latest developments is vital to patient care. Below is a patient case of a 7-year-old female with atopic dermatitis. Have a look at the case details, then tune in as LiVDerm faculty member Brittany Craiglow, MD and other experts discuss their thoughts and recommendations on the case.
Patient Presentation and History
7-year old female
Diagnosed with moderate atopic dermatitis six months ago
Patches on the face and elbow worsening
Experiencing bullying at school
PCP prescribed a combination regimen of emollients, moisturizers, and hydrocortisone 2% cream
After three months was switched to tacrolimus 0.03% ointment
Burning sensation when applying therefore not adherent to the regimen
Rashes are getting worse
Experiencing a sensitivity to hot and cold temperatures
Parents are concerned about the long-term use of steroids
